Checkpoint inhibitor

CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries

Friday, March 27, 2020 - 12:00am

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China.

Key Points: 
  • CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China.
  • CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC).
  • In addition, CG Oncology is studying the use of CG0070 in combination with immune checkpoint inhibitors in bladder cancer and other solid tumors.
  • In addition, CG Oncology is exploring the use of CG0070 in combination with immune checkpoint inhibitors in different solid tumors.

Scholar Rock Announces Publication in Science Translational Medicine of Preclinical Data Detailing a Potent and Selective Inhibitor of TGFβ1 Overcoming Primary Resistance to Checkpoint Inhibition

Thursday, March 26, 2020 - 11:30am

Selective inhibition of latent TGF1 activation with SRK-181 has demonstrated an improved safety profile as compared to pan-TGF inhibitors.

Key Points: 
  • Selective inhibition of latent TGF1 activation with SRK-181 has demonstrated an improved safety profile as compared to pan-TGF inhibitors.
  • SRK-181 is a potent and highly selective inhibitor of TGF1 activation and is an investigational product candidate being developed to overcome primary resistance to checkpoint inhibitor therapy, such as anti-PD-(L)1 antibodies.
  • TGF1 is the predominant TGF isoform expressed in many human tumors, particularly for those tumors where checkpoint therapies are currently approved.
  • By overcoming this immune cell exclusion, Scholar Rock believes SRK-181 has the potential to induce tumor regression when administered in combination with anti-PD-(L)1 therapy.

BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic

Thursday, March 26, 2020 - 10:30am

Phase I/IIa clinical study of BriaCells lead candidate, Bria-IMT, with Incyte Corporations immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic.

Key Points: 
  • Phase I/IIa clinical study of BriaCells lead candidate, Bria-IMT, with Incyte Corporations immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic.
  • BERKELEY, Calif. and VANCOUVER, British Columbia, March 26, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BriaCell or the Company) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announce that the Phase I/IIa clinical study of Bria-IMT with Incyte Corporations immune checkpoint inhibitor, INCMGA00012 is ongoing and recruiting patients amidst the COVID-19 pandemic.
  • BriaCells clinical trial is ongoing throughout the COVID-19 pandemic.
  • We are confident that the participating clinical sites in BriaCells clinical trial are fully compliant with state-specific regulations, and will take every appropriate measure to meet and exceed safety standards for their patients amid the COVID-19 pandemic.

New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy

Friday, March 20, 2020 - 5:05am

This case study examines a patient who developed CSCC seven years after an initial kidney transplantation.

Key Points: 
  • This case study examines a patient who developed CSCC seven years after an initial kidney transplantation.
  • Use of checkpoint inhibitors in transplant patients is new, and this is the first case of a re-transplanted patient.
  • I am glad we had AlloSure to monitor the health of this patient, said Daniel Brennan, MD, Johns Hopkins.
  • This AJT published case study is exciting because it provides evidence that patients who have previously received immune checkpoint inhibitor therapy for cancer can successfully undergo kidney retransplantation.

NKMax America to Present at the Upcoming NIH-AACR Cancer, Autoimmunity, and Immunology Conference

Wednesday, March 18, 2020 - 12:00am

Presentation Title: Use of SNK-01 (Autologous Non-Genetically Modified Natural Killer Cells with Increased Cytotoxicity) in Combination with Pembrolizumab in Solid Tumors to Improve Tumor Response and Decrease Checkpoint Inhibitor Related Toxicity.

Key Points: 
  • Presentation Title: Use of SNK-01 (Autologous Non-Genetically Modified Natural Killer Cells with Increased Cytotoxicity) in Combination with Pembrolizumab in Solid Tumors to Improve Tumor Response and Decrease Checkpoint Inhibitor Related Toxicity.
  • Dr. Song will discuss the significant role that natural killer cells play in improving overall tumor response to checkpoint inhibitors for both PD-L1 positive and PD-L1 negative tumors.
  • Dr. Song will highlight NKMax Americas proprietary natural killer cell expansion/activation technology and discuss NKMaxs clinical experience with combination immune checkpoint-based therapy.
  • NKMax America Inc. is a clinical stage biotechnology company dedicated to restoring and enhancing overall immune integrity.

Global Immune Checkpoint Inhibitors (ICI) Market Report 2020 Featuring FDA Approved Keytruda, Opdivo, Tecentriq, Imfinzi, Yervoy, Libtayo, and Bavencio

Monday, March 16, 2020 - 1:15pm

DUBLIN, March 16, 2020 /PRNewswire/ -- The "Immune Checkpoint Inhibitors Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 16, 2020 /PRNewswire/ -- The "Immune Checkpoint Inhibitors Market" report has been added to ResearchAndMarkets.com's offering.
  • The market took off in 2015, the first full year on the market of Keytruda and Opdivo, the two PD-1 inhibitors from Merck and Bristol-Myers Squibb, respectively.
  • However, China has a local industry that has managed to launch four PD-1 monoclonal antibody checkpoint inhibitors in 2019.
  • Immune checkpoint inhibitors are tumor agnostic and represent some of the most advanced treatments available to patients with cancer.

MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL‑CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours

Tuesday, March 3, 2020 - 11:00am

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours.

Key Points: 
  • MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours.
  • The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients.
  • The drug candidate is also being investigated in an ongoing multi-centre Phase 1b clinical trial in patients with advanced liver cancer in combination with sorafenib.
  • We are excited to take the next step and test MTLCEBPA in additional cancer populations in a potentially synergistic combination with an anti-PD1 checkpoint inhibitor.

Realtor Credits New Immunotherapy for Destroying the Cancer That Threatened His Life

Monday, March 2, 2020 - 1:55pm

The cancer tells our immune system and T-cells to ignore the tumor alone instead of directly attacking it.

Key Points: 
  • The cancer tells our immune system and T-cells to ignore the tumor alone instead of directly attacking it.
  • Immunotherapies which includes checkpoint inhibitors encourage our immune systems to recognize and kill the cancer.
  • These studies involve combinations with checkpoint inhibitors for the treatment of breast cancer, multiple myeloma, and pancreatic cancer.
  • Synthetic biotic medicines are microbes genetically engineered to counter the biology that drives diseases such as hyperammonemia and forms of cancer.

Realtor Credits New Immunotherapy for Destroying the Cancer That Threatened His Life

Monday, March 2, 2020 - 1:55pm

The cancer tells our immune system and T-cells to ignore the tumor alone instead of directly attacking it.

Key Points: 
  • The cancer tells our immune system and T-cells to ignore the tumor alone instead of directly attacking it.
  • Immunotherapies which includes checkpoint inhibitors encourage our immune systems to recognize and kill the cancer.
  • These studies involve combinations with checkpoint inhibitors for the treatment of breast cancer, multiple myeloma, and pancreatic cancer.
  • Synthetic biotic medicines are microbes genetically engineered to counter the biology that drives diseases such as hyperammonemia and forms of cancer.

Accidental T-cell Discovery Represents "A New Frontier" in Cancer Treatment

Friday, February 28, 2020 - 2:00pm

LOS ANGELES, Feb. 28, 2020 /PRNewswire/ -- USA News Group While it has not yet been tested in patients, researchers say an accidental T-cell discovery represents "an exciting new frontier" in cancer treatment.

Key Points: 
  • LOS ANGELES, Feb. 28, 2020 /PRNewswire/ -- USA News Group While it has not yet been tested in patients, researchers say an accidental T-cell discovery represents "an exciting new frontier" in cancer treatment.
  • T-cells are an important factor in several new and emerging areas of cancer treatment technology.
  • These studies involve combinations with checkpoint inhibitors for the treatment of breast cancer, multiple myeloma, and pancreatic cancer.
  • The company's liver cancer study of the drug namodenoson was recently selected by the International Liver Cancer Association conference.